Earnings bulletin: Johnson & Johnson's second quarter of 2019

nyse
J&J sales traded slightly down Tuesday after the company reported second quarter results. (Pixabay)

Johnson & Johnson kicked off the second-quarter earnings season Tuesday, reporting that its pharma unit outperformed struggling consumer healthcare and medical device segments. Pharma posted sales growth of 1.7% and operational growth of 4.4% to hit $10.53 billion in sales.

Across J&J's entire business, the company's revenue sank 1.3% to $20.56 billion. At the same time, earnings jumped 41.8% thanks to a sale in medical devices that brought in about $2 billion before taxes. That revenue figure and adjusted earnings per share of $2.58 both beat analyst estimates.

With the performance, Johnson & Johnson increased its sales guidance for the year to between $82.4 billion and $83.2 billion, up from April's guidance of $82 billion to $82.8 billion.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

RELATED: J&J execs have plenty to brag about in pharma. Why downplay Xarelto, Zytiga woes?

Within pharma, blockbuster immunology med Remicade continued to slump thanks to biosimilar pressure; sales for that med sank 16.2% globally to $1.1 billion for the quarter. Zytiga suffered from generic competition, and Xarelto posted a 19% decline in the U.S. thanks to new discounting rules in Medicare.

On the flip side, Stelara, Tremfya, Invega, Darzalex, Imbruvica, Opsumit, Uptravi, and Prezista grew by double digit percentages.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.